title: IDH1/2 mutation detection in gliomas.
abstract: Somatic mutations of isocitrate dehydrogenase 1 and 2 (IDH1/2) are strongly associated with pathological subtypes, genetic profiles, and clinical features in gliomas. The IDH1/2 status is currently regarded as one of the most important molecular markers in gliomas and should be assessed accurately and robustly. However, the methods used for IDH1/2 testing are not fully standardized. The purpose of this paper is to review the clinical significance of IDH1/2 mutations and the methods used for IDH1/2 testing. The optimal method for IDH1/2 testing varies depending on a number of factors, including the purpose, sample types, sample number, or laboratory equipment. It is therefore important to acknowledge the advantages and disadvantages of each method.
authors.affiliation: Department of Neurosurgery and Neuro-Oncology, National Cancer Center Hospital, Tokyo, Japan, h-arita@nsurg.med.osaka-u.ac.jp.
authors.forename: Hideyuki
authors.initials: H
authors.lastname: Arita
authors.forename: Yoshitaka
authors.initials: Y
authors.lastname: Narita
authors.forename: Akihiko
authors.initials: A
authors.lastname: Yoshida
authors.forename: Naoya
authors.initials: N
authors.lastname: Hashimoto
authors.forename: Toshiki
authors.initials: T
authors.lastname: Yoshimine
authors.forename: Koichi
authors.initials: K
authors.lastname: Ichimura
mesh_terms: D044127:Epigenesis, Genetic / Q000235:genetics*; D056726:Genetic Association Studies / Q000379:methods*; D005819:Genetic Markers / Q000235:genetics*; D005820:Genetic Testing / Q000379:methods; D005910:Glioma / Q000235:genetics* / Q000473:pathology; D006801:Humans; D007521:Isocitrate Dehydrogenase / Q000235:genetics*; D009154:Mutation; D011379:Prognosis; D017421:Sequence Analysis / Q000379:methods
chemical_list: D005819:Genetic Markers; C538784:IDH2 protein, human; D007521:Isocitrate Dehydrogenase; C543588:IDH1 protein, human